PACB - Pacific Biosciences of California, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Menlo Park,
United States
Type: Equity
PACB price evolution
PACB
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $180.21 | $385.95 | $209.59 | $354.13 |
| Short term investments | $451.5 | $382.14 | $620.58 | $521.06 |
| Net receivables | $36.62 | $30.49 | $24.03 | $29.59 |
| Inventory | $56.68 | $68.26 | $67.61 | $61.95 |
| Total current assets | $742.05 | $882.3 | $935.55 | $981.11 |
| Long term investments | $2.42 | $2.42 | $2.42 | $2.92 |
| Property, plant & equipment | $69.03 | $74.95 | $76.76 | $79.08 |
| Goodwill & intangible assets | $919.25 | $925.68 | $819.75 | $819.99 |
| Total noncurrent assets | $1003.97 | $1016.06 | $912.08 | $915.31 |
| Total investments | $453.93 | $384.56 | $623 | $523.98 |
| Total assets | $1746.01 | $1898.35 | $1847.63 | $1896.42 |
| Current liabilities | ||||
| Accounts payable | $15.06 | $16.11 | $16.51 | $17.39 |
| Deferred revenue | $21.87 | $27.43 | $29.98 | $32.72 |
| Short long term debt | $9.59 | $9.46 | $9.24 | $9.02 |
| Total current liabilities | $95.03 | $183.96 | $271.41 | $265.67 |
| Long term debt | $923.85 | $926.1 | $928.39 | $935.81 |
| Total noncurrent liabilities | $949.68 | $950.65 | $934.22 | $938.63 |
| Total debt | $933.44 | $935.56 | $937.64 | $944.83 |
| Total liabilities | $1044.71 | $1134.61 | $1205.63 | $1204.3 |
| Shareholders' equity | ||||
| Retained earnings | -$1839.08 | -$1757.06 | -$1690.19 | -$1620.36 |
| Other shareholder equity | $0.22 | -$1.84 | -$2.69 | -$1.92 |
| Total shareholder equity | $701.3 | $763.74 | $642 | $692.12 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $180.21 | $325.39 | $461.23 | $82.45 |
| Short term investments | $451.5 | $447.23 | $583.67 | $237.2 |
| Net receivables | $36.62 | $18.79 | $24.24 | $16.84 |
| Inventory | $56.68 | $50.38 | $24.6 | $14.23 |
| Total current assets | $742.05 | $852.07 | $1101.13 | $355.59 |
| Long term investments | $2.42 | $2.92 | $4.59 | $3.5 |
| Property, plant & equipment | $69.03 | $81.34 | $79.12 | $54.85 |
| Goodwill & intangible assets | $919.25 | $820.22 | $820.95 | |
| Total noncurrent assets | $1003.97 | $915.01 | $905.84 | $58.39 |
| Total investments | $453.93 | $450.15 | $588.27 | $240.7 |
| Total assets | $1746.01 | $1767.09 | $2006.97 | $413.98 |
| Current liabilities | ||||
| Accounts payable | $15.06 | $12.03 | $11 | $3.58 |
| Deferred revenue | $21.87 | $32.29 | $36.03 | $10.29 |
| Short long term debt | $9.59 | $8.89 | $7.71 | $4.33 |
| Total current liabilities | $95.03 | $263.33 | $71.71 | $38.5 |
| Long term debt | $923.85 | $896.68 | $946.04 | $37.67 |
| Total noncurrent liabilities | $949.68 | $940.85 | $1144.27 | $39.99 |
| Total debt | $933.44 | $946.64 | $953.75 | $42 |
| Total liabilities | $1044.71 | $1204.18 | $1215.98 | $78.49 |
| Shareholders' equity | ||||
| Retained earnings | -$1839.08 | -$1532.34 | -$1218.09 | -$1036.87 |
| Other shareholder equity | $0.22 | -$4.76 | -$1.09 | $0.09 |
| Total shareholder equity | $701.3 | $562.9 | $790.99 | $335.49 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $58.36 | $55.69 | $47.57 | $38.9 |
| Cost of revenue | $48.79 | $37.79 | $32.03 | $29.14 |
| Gross Profit | $9.57 | $17.9 | $15.55 | $9.76 |
| Operating activities | ||||
| Research & development | $44.54 | $47.51 | $46.17 | $48.94 |
| Selling, general & administrative | $46 | $43.43 | $40.57 | $39.82 |
| Total operating expenses | $96.02 | $100.67 | $86.75 | $88.76 |
| Operating income | -$86.45 | -$82.76 | -$71.2 | -$79 |
| Income from continuing operations | ||||
| EBIT | -$79.17 | -$73.99 | -$66.28 | -$84.39 |
| Income tax expense | -$0.72 | -$10.71 | ||
| Interest expense | $3.57 | $3.59 | $3.55 | $3.63 |
| Net income | ||||
| Net income | -$82.02 | -$66.87 | -$69.83 | -$88.02 |
| Income (for common shares) | -$82.02 | -$66.87 | -$69.83 | -$88.02 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $200.52 | $128.3 | $130.51 | $78.89 |
| Cost of revenue | $147.74 | $79.27 | $71.65 | $46.33 |
| Gross Profit | $52.78 | $49.03 | $58.86 | $32.57 |
| Operating activities | ||||
| Research & development | $187.17 | $193 | $112.9 | $64.15 |
| Selling, general & administrative | $169.82 | $160.85 | $124.12 | $72.8 |
| Total operating expenses | $372.19 | $353.85 | $268.15 | $136.95 |
| Operating income | -$319.41 | -$304.82 | -$209.29 | -$104.39 |
| Income from continuing operations | ||||
| EBIT | -$303.82 | -$299.56 | -$262.34 | $29.67 |
| Income tax expense | -$11.42 | -$93.65 | ||
| Interest expense | $14.34 | $14.69 | $12.53 | $0.27 |
| Net income | ||||
| Net income | -$306.74 | -$314.25 | -$181.22 | $29.4 |
| Income (for common shares) | -$306.74 | -$314.25 | -$181.22 | $29.4 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$82.02 | -$66.87 | -$69.83 | -$88.02 |
| Operating activities | ||||
| Depreciation | $11.7 | $5.46 | $4.86 | $4.52 |
| Business acquisitions & disposals | -$0.1 | |||
| Stock-based compensation | $16.58 | $19.69 | $17.89 | $17.95 |
| Total cash flows from operations | -$57.56 | -$65.18 | -$41.74 | -$94.69 |
| Investing activities | ||||
| Capital expenditures | -$2.02 | -$0.83 | -$2.27 | -$3.72 |
| Investments | -$64.55 | $243.25 | -$96.32 | -$68.83 |
| Total cash flows from investing | -$66.58 | $242.32 | -$98.59 | -$72.55 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.94 | $4.56 | $2.59 | $196.44 |
| Net borrowings | -$0.49 | -$0.97 | -$7.3 | -$0.45 |
| Total cash flows from financing | -$81.6 | -$0.78 | -$4.71 | $195.99 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$205.74 | $176.36 | -$145.05 | $28.75 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$306.74 | -$314.25 | -$181.22 | $29.4 |
| Operating activities | ||||
| Depreciation | $26.53 | $17.32 | $11.59 | $9.3 |
| Business acquisitions & disposals | -$0.1 | -$319.79 | ||
| Stock-based compensation | $72.12 | $78.61 | $73.36 | $17.53 |
| Total cash flows from operations | -$259.17 | -$263.21 | -$111.18 | $19.5 |
| Investing activities | ||||
| Capital expenditures | -$8.84 | -$16.75 | -$5.93 | -$1.04 |
| Investments | $13.55 | $133.01 | -$352.81 | -$218.28 |
| Total cash flows from investing | $4.6 | $116.08 | -$678.53 | -$219.32 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $204.52 | $11.23 | $326.65 | $233.84 |
| Net borrowings | -$9.22 | -$1.61 | $895.17 | -$16 |
| Total cash flows from financing | $108.89 | $9.62 | $1169.58 | $251.84 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$145.68 | -$137.51 | $379.87 | $52.02 |
News
|
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
Zacks via Yahoo Finance
3 Apr 2024
|
|
Rare Stock Picks In March 2024 - From 24 Discerning Analysts
Seeking Alpha
3 Apr 2024
|
|
Aadi Bioscience executive chairman sells over $90k in company stock
Investing.com
2 Apr 2024
|
|
Cathie Wood's ARK adds more Tesla stock, sells DraftKings
Investing.com
2 Apr 2024
|
|
Cathie Wood's ARK makes major moves in Tesla stock, sells Robinhood
Investing.com
1 Apr 2024
|
|
11 Oversold NASDAQ Stocks To Buy Right Now
Insider Monkey via Yahoo Finance
13 Mar 2024
|
|
PacBio's (PACB) New Panel to Aid Its Clinical Research Solution
Zacks via Yahoo Finance
13 Mar 2024
|
|
PacBio unveils gene panel for neurological disease study By Investing.com
Investing.com
12 Mar 2024
|
|
Director David Meline Acquires 40,000 Shares of Pacific Biosciences of California Inc (PACB)
GuruFocus.com via Yahoo Finance
6 Mar 2024
|
|
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance
29 Feb 2024
|
Fundamentals
| Market cap | $374.42M |
|---|---|
| Enterprise value | $1.13B |
| Shares outstanding | 267.44M |
| Revenue | $200.52M |
|---|---|
| EBITDA | -$277.28M |
| EBIT | -$303.82M |
| Net Income | -$306.74M |
| Revenue Q/Q | 113.35% |
| Revenue Y/Y | 56.29% |
| P/E ratio | -1.22 |
|---|---|
| EV/Sales | 5.62 |
| EV/EBITDA | -4.07 |
| EV/EBIT | -3.71 |
| P/S ratio | 1.87 |
| P/B ratio | 0.53 |
| Book/Share | 2.62 |
| Cash/Share | 0.67 |
| EPS | -$1.15 |
|---|---|
| ROA | -16.61% |
| ROE | -43.83% |
| Debt/Equity | 1.49 |
|---|---|
| Net debt/EBITDA | -3.12 |
| Current ratio | 7.81 |
| Quick ratio | 7.21 |